We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 60,335 | 08:00:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 29/9/2020 07:52 | The extra detail on the SG016 trial is interesting. They appear to now be saying the trial met its primary endpoint in both the ITT and PP groups. Managed access in the EU and UK is a small piece of the jigsaw puzzle. You'd have to assume there's another clinical trial planned in the UK, and possibly in the US too, so it would only apply to those who couldn't access the trial. An interesting question will be the price. Presumably enough to cover costs? | mirako | |
| 29/9/2020 07:52 | Long or short, never forget the three golden rules of investing: Rule 1) Never lose money Rule 2) Don't ever listen to amaretto1 Rule 3) Don't forget the first two rules. | notknowing | |
| 29/9/2020 07:49 | Yeh, yeh... just as well you're not invested yet. Or are u short? | investordave |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
